About Qed therapeutics
QED Therapeutics is a biopharmaceutical company that is dedicated to discovering innovative solutions for FGFR-driven cancers and diseases. The company's mission is to provide patients with more possibilities by developing effective treatments that target the underlying causes of these conditions.
FGFR (Fibroblast Growth Factor Receptor) is a protein that plays a crucial role in cell growth, differentiation, and survival. However, when this protein becomes overactive or mutated, it can lead to the development of various types of cancer and other diseases. QED Therapeutics focuses on developing therapies that specifically target FGFR abnormalities in order to treat these conditions.
The company was founded in 2017 by a team of experienced scientists and industry professionals who recognized the urgent need for new treatments for FGFR-driven cancers and diseases. Since then, QED Therapeutics has made significant progress in its research efforts and has established itself as a leader in this field.
One of the key strengths of QED Therapeutics is its deep understanding of the biology behind FGFR-driven cancers and diseases. The company's scientists have extensive expertise in this area, which allows them to develop targeted therapies that are tailored to each patient's specific needs.
QED Therapeutics' flagship product candidate is Infigratinib (BGJ398), an oral medication designed to inhibit abnormal FGFR signaling pathways. Infigratinib has shown promising results in clinical trials for several types of cancer, including cholangiocarcinoma (bile duct cancer) and urothelial carcinoma (bladder cancer). The drug has also shown potential as a treatment for other FGFR-driven diseases such as achondroplasia (a type of dwarfism).
In addition to its work on Infigratinib, QED Therapeutics is actively pursuing other research programs aimed at developing new therapies for FGFR-driven cancers and diseases. These programs include collaborations with leading academic institutions and industry partners.
QED Therapeutics' commitment to innovation extends beyond its scientific research efforts. The company also places great emphasis on patient advocacy and engagement. By working closely with patients, caregivers, advocacy groups, healthcare providers, regulators, and policymakers, QED Therapeutics aims to ensure that its products are developed with patients' needs at the forefront.
Overall,Qed therapeutis stands out among biopharma companies due their dedication towards finding solutions towards FGRF driven cancers & disease inorder give patients more possibilities.Qed therapeutis continues making strides through their flagship product candidate infigratinib & active pursuit towards researching new therapies.Qed therapeutis not only focuses on scientific research but also places great emphasis on patient advocacy & engagement which makes them stand out from others .
qedtx.com
